EANS-News: Oxygen Biotherapeutics Inc.
Study Shows Marked Neuroprotective
Effects of Oxycyte® Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury
Durham, NC (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Company Information/Research & Development/Biotechnology
Press Release
Oxygen Biotherapeutics Inc.:
Study Shows Marked Neuroprotective Effects of Oxycyte® Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury
DURHAM, NC, June 3, 2010 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today reported on the results of two University of Miami Miller School of Medicine studies involving the Company´s third-generation perfluorocarbon, Oxycyte® perfluorocarbon emulsion. Both study reports showed that Oxycyte® has a marked neuroprotective effect in a rat model of spinal cord injury.
"Having proof-of-concept is a first step toward moving Oxycyte down the spinal cord injury track. The positive results observed in both studies warrant efforts to pursue partnerships to conduct clinical studies of Oxycyte in spinal cord injury in the future," said Gerald Klein, Chief Medical Officer for Oxygen Biotherapeutics.
The studies showed that histologically, Oxycyte improves the volume of preserved neuronal tissue in the spinal cord following injury; a favorable improvement in functional recovery, as assessed by footprint analysis six weeks post treatment, has also been observed.
The study entitled "Possible Role of Hyperbaric Oxygen Therapy (HBO) and Oxycyte After Spinal Cord Injury in Rats," will be part of the poster sessions at the National Neurotrauma Symposium on June 14-16, 2010 at the Paris Hotel in Las Vegas. Results of the first study entitled "Evaluation of the Neuroprotective and Behavioral Effects of the Perfluorocarbon Oxycyte After Spinal Cord Injury (SCI) in the Rat" were presented in September 2009 at the annual National-International Neurotrauma Symposium by Dr. Ross Bullock, University of Miami Miller School of Medicine. Both studies received funding from Oxygen Biotherapeutics.
Oxycyte emulsion is a proprietary therapeutic oxygen carrier. It is a perfluorocarbon emulsified with water and a surfactant that is delivered intravenously.
According to statistics from various studies compiled by the National Spinal Cord Injury Statistical Center in Birmingham, AL, an estimated 12,000 new cases of spinal cord injury occur each year in the United States; and the number of people living in the United States with SCI is estimated to be approximately 259,000 people. According to a study initiated by the Christopher & Dana Reeve Foundation, approximately 6 million people worldwide are living with paralysis that is largely a result of SCI.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte that is being formulated for both intravenous and topical delivery. In April, the company launched its first cosmetic product, Dermacyte Oxygen Concentrate. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, and topical wound healing. More information is available at www.oxybiomed.com or www.buydermacyte.com.
Caution Regarding Forward-Looking Statements.
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the plans for the expansion of the Dermacyte product line and the timing of the introduction of those new products. The forward looking statements are subject to a number of risks and uncertainties including matters beyond the company´s control that could lead to delays in the new product introductions and customer acceptance of these new products and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current report on Form 8-K on May 4, 2010. Furthermore, there can be no assurance that such plans will lead to meaningful sales of Dermacyte or generate any revenue for the company. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
end of announcement euro adhoc
Further inquiry note:
For further information please contact:
Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
2530 Meridian Pkwy, 3rd floor
Durham, NC 27713
Direct Telephone: +1 919 806 4405
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com
Branche: Biotechnology
ISIN: US69207P2092
WKN: A0YD9Z
Börsen: New York / Nasdaq